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AIM:  
To compare the clinical outcomes among critically ill patients with hospital 
acquired infections (ventilator associated pneumonia and catheter related 
blood stream infections) caused by Acinetobacter spp. with HAI caused by 
other bacterial pathogens at a tertiary-care teaching hospital in South India  
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OBJECTIVES 
Primary outcome:  
a. To compare the in-hospital mortality rates of Hospital Acquired infections 
(HAI) caused by Acinetobacter spp. with that of other HAI caused by non-
Acinetobacter bacterial HAI’s among critically ill patients admitted in ICU 
and HDU. 
Secondary outcomes:  
b. Microbiological Measurements:  
i. To study the proportion of ventilator associated pneumonia(VAP) 
and blood stream infection (BSI) caused by Acinetobacter species 
in the Medical Intensive Care unit (MICU) and the Medical High 
dependency care unit (MHDU) and Surgical Intensive Care unit 
(SICU). 
ii. To study the antibiotic susceptibility profiles of the isolates of 
Acinetobacter species  
 
c. Clinical Outcome: To compare the following between Acinetobacter spp. 
and Non-Acinetobacter hospital acquired infections 
i. Duration of mechanical ventilation ( assessed by duration of 
ventilator free days)   
ii. Duration of ICU stay   
iii. Duration of  hospital stay  
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 PURPOSE: Acinetobacter species is being identified as a causative agent in increasingly 
larger proportion of hospital acquired infections (HAI). They are most commonly seen in an 
ICU setting, among critically ill patients. We attempted to answer the question of whether 
HAI caused by Acinetobacter species has poorer clinical outcomes when compared to HAI 
caused by other bacterial pathogens.  
 
OBJECTIVES: 
To compare the in-hospital mortality rates, duration of mechanical ventilation (assessed by 
duration of ventilator free days), duration of ICU stay and duration of  hospital stay of 
patients with Hospital Acquired infections (HAI) caused by Acinetobacter spp. with HAI 
by other organisms.  
 
METHODS: 
This was a prospective cohort study among adult patients who developed a new fever 48 
hours after admission in the Intensive Care Unit. If the patient fulfilled criteria for VAP or 
CR-BSI, then the patient was recruited into the study. The patients were followed up until 
death or discharge. The microbiological and clinical outcomes that were relevant were 
collected and analysed.  
RESULTS: 
126 patients developed a HAI, during the course of the study period, of which 93 (73.8%) 
were VAP and 33 (26.1%) were CR-BSI, 77 (61%) developed Acinetobacter related HAI and 
49 (39%) were Non-Acinetobacter related HAI. There were 44 deaths (57.1%) among the 
Acinetobacter group compared to 33 (42.9%) in the Non-Acinetobacter group but this 
difference was not statistically significant (CI- 0.935-3.99, p=0.074). 67 out of 93 cases of 
VAP (72%) were caused by Acinetobacter spp. The Acinetobacter group had more patients 
with 0 ventilator-free days (duration of mechanical ventilation >28 days or death) when 
compared to the Non-Acinetobacter group (45 patients, 57.2% vs 12 patients, 46.2%, p= 
0.03).The duration of ICU stay and hospital stay was not significantly different between the 
two groups.  
  
CONCLUSIONS 
In our cohort study of critically ill medical and surgical patients with VAP or CR-BSI, we 
found no significant increase in mortality rates among those with Acinetobacter related HAI’s 
compared to those with Non-Acinetobacter related HAI. However we found that the patients 
with Acinetobacter related HAI’s had significantly poorer ventilator outcomes (death or >28 
days on Ventilator) but no significant increase in ICU or Hospital stay. 
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INTRODUCTION 
The evolution of technology and modern medicine over the last century has led to a 
transformation in the practice of medicine. There has been a dramatic increase in life 
expectancy, and hitherto untreatable diseases have become easily treatable and even curable 
such that the affected person can return to a normal and productive life.  
 
However all these apparently miraculous cures come at a price. The elimination of old foes 
with modern medicine has led to the emergence of new ones, as well as re-emergence of old 
enemies which have adapted to live in their new environment. The age of ‘super-antibiotics’ 
have been short lived due to the emergence of ‘super-bugs’ that have rapidly attained 
resistance to them.   
 
In the last half century the number of intensive care units around the world has increased, and 
with it has increased the accessibility of their services. The Society for critical care medicine 
has quoted an increase in ICU bed numbers from 67,357 in 2007 to 944,277 beds from 2007-
2009 in the United states. (1). Numbers in India are not yet clearly defined, and the data 
collection for the same still in progress as of 2014. (2) But one thing that is clear is that the 
numbers, the access and the awareness about the need for critical care in a developing 
country like India is increasing, although still far from adequate to meet the needs of the 
country.  
 
In this setting, the emergence of ICU acquired infections plays a major role. In a country like 
India, the epidemiology of patients admitted in the ICU is drastically different from that in 
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the west. Tropical infections such as malaria, Leptospirosis etc. form a large part of our ICU 
disease profile.(3) These infections have a rapid progression and severity, but since the 
affected individuals are commonly younger, and the disease state potentially curable, there is 
a better associated prognosis. In this background a patient developing an ICU acquired 
infection, especially one that is multidrug resistant, changes their prognosis drastically.  
The emergence of hospital associated and device associated infections has increased the 
world over.(4) These infections have been shown to adversely affect patient outcomes. Hence 
there is an urgent need for study of mechanisms to prevent these infections, as well as 
methods to treat the affected patients. There is a dearth of data in India regarding 
Acinetobacter infections, their susceptibility patterns and their associated mortality or 
morbidity.  
 
This study aims to better understand the morbidity and mortality associated with Health care 
associated Acinetobacter infections. It also aims to document the antibiotic susceptibility 
patterns of these infections in a tertiary care center in South India.     
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HEALTH CARE ASSOCIATED INFECTIONS 
Definition 
 
“Healthcare-associated infections (HCAI) are infections occurring after exposure to 
healthcare, often, but not always, as a consequence of this exposure. Hospital acquired 
infections (HAI), also referred to as ‘nosocomial infections’ (NI) or simply ‘hospital 
infections’, are infections occurring during a stay in hospital that were neither present nor 
incubating at the time of hospital admission.
i
 
 
Since the usual duration of time required to differentiate a community acquired infection 
which is still incubating, from a newly acquired infection after arrival at the hospital is 
about 48 hours, this is usually taken as the cut off time in epidemiological surveillance 
systems.  
 
Epidemiology 
Nosocomial infections are a major public health and patient safety issue. With increasing 
hospitalisation, the incidence of hospital acquired infections as well as the cost involved in 
patient care has become major issues especially in the west.  A study conducted in 2002 
estimated the number of HAI’s in the United States in 1 year to be approximately 1.7 
million, with 98,987 HAI associated deaths. (5) The direct costs to the healthcare system in 
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supporting these patients are also immense, with estimates ranging between 28.4-33.8 
billion dollars a year in the United States. (6) 
In 2011 the World Health Organisation undertook a Systematic review of the literature 
regarding health care associated infections and found that there is a scarcity of information 
regarding the magnitude of hospital acquired infections. Most of the data available 
worldwide is from the developed countries. Even the little data that is available from the 
developing nations usually represents only single center or a single local area incidence 
and prevalence.  Hence the burden upon the patient, their families and the healthcare 
system is under-recognised.   
 
The available literature indicates a 2-3 fold increased incidence of ICU acquired infections 
in low and middle income countries as compared to the high income countries. (4)(7)In 
addition, a patient who develops a nosocomial infection has an additional length of hospital 
stay that can vary from 5-29.5 days, with  excess mortality ranging from 18%-30%. (4) 
In India studies have estimated an incidence rate of 6-17% among patients admitted in the 
ICU, which included both surgical site infections as well as device associated infections. 
(8)(7).Device associated infections such as Catheter related blood stream infections ( 
CRBSI), Ventilator Associated Pneumonia ( VAP) and Catheter related Urinary tract 
infections ( CRUTI) form a large majority of these infections.  Of these VAP and CRBSI 
have been found to have the highest incidence rates ranging from 21 to 32 and 0.48 to 16 
per 1000 device days respectively. (9)(8) 
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VENTILATOR ASSOCIATED PNEUMONIA 
Definition 
Precisely defining a Ventilator Associated Pneumonia (VAP) is an ongoing debate due to 
the lack of objective clearly identifiable criteria that can differentiate a VAP from a whole 
host of pulmonary disorders that can affect a critically ill patient on a ventilator.  Over the 
years, numerous societies and institutions have put forward different criteria for the 
diagnosis of VAP. 
Diagnosis- CPIS score 
A 2005 guideline on management of hospital acquired infections was jointly put forward 
by the American Thoracic Society and the Infectious Disease Society of America, which 
broadly defined a VAP as an pneumonia occurring in mechanically ventilated patients after 
48 hours of intubation, with a new or progressing infiltrate, signs of systemic 
inflammation, changes in sputum characteristics and a causative organism which is 
identified.(10) The above criteria formed the backbone for numerous other criteria and 
definitions for identification of VAPs. Among these the Clinical Pulmonary Infection 
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Score (CPIS), is one of the most widely used methods for diagnosis. It was initially put 
forward in 1991(11) and it uses a combination of weighted clinical and microbiological 
criteria for the diagnosis of VAP. (Refer Figure 1).   
 
Figure 1  
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A study done to assess the accuracy of the CPIS score showed a sensitivity of 45.8% and 
specificity of 60.4%, when used at a cut off value of 6, and using autopsy findings as the 
gold standard. (12) Earlier studies showed variability in sensitivity and specificity ranging 
from 72% to 77% and 85% to 42% respectively. (13,14) In addition, this score was found 
to be subjective, with high inter observer variability ( kappa-0.16) (15).  The drawbacks of 
poor sensitivity and subjectivity of the scoring system has prompted a re-look at how we 
diagnose ventilator associated pneumonias.  
 
CDC diagnostic guidelines 
 
In 2011 the Centers for Disease Control and Prevention (CDC) convened a working group, 
to propose a new approach to the diagnosis of ventilator associated pneumonias. The 
primary purpose of this group was to make the definition objective, streamlined and 
potentially automatable. This new definition, which was implemented in January 2013 by 
the National Healthcare Safety Network (NHSN), identifies a broad range of conditions 
identified as Ventilator Associated Events (VAE). Within this are three definition tiers 
called Ventilator Associated Condition ( VAC), Infection-related Ventilator Associated 
Condition ( IVAC)  and Possible and Probable VAP.(16)  
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Pathophysiology 
 
An understanding of the potential mechanisms contributing to the development of a VAP 
is essential for formulating preventive strategies and improving patient care. The 
Endotracheal tube itself is an important factor for the development of a VAP, as it impairs 
the mucociliary clearance of secretions, while itself acting as an irritant thereby increasing 
the respiratory secretions. The cuff of the ET tube can prevent major aspirations, although 
the inability to provide a perfect seal, causing leakage of secretions from the sides of the 
cuff, facilitating micro-aspirations. These micro-aspirations are carried along by gravity to 
the dependent portions of the lung, where they settle, thus forming a nidus for 
infection.(17)  
 
In addition the ET tube also serves as a focus of infection by being a foreign body 
amenable to biofilm formation by pathogenic organisms. This biofilm is a complex matrix 
of polysaccharides, protein and DNA which serve as a mechanical barrier between the 
micro-organisms and the host.(18) This in turn facilitates growth of the organisms thus 
increasing risks of developing an infection. The biofilm also facilitates development of 
antibiotic resistance, by complex interactions between organisms, as well as by decreasing 
the direct access of antimicrobials to the organisms.(19) Since most biofilms are produced 
by gram-negative organisms, it seems logical that they are the most common causative 
agents for VAP.     
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Finally, the host-microbe interaction and the balance between the two plays a vital role in 
determining the course of the infection and the ultimate outcome for the patient.(20) 
 
Clinical significance 
 
Ventilator associated pneumonias are associated with an increased mortality, with 
estimates of attributable mortality being approximately 10%(21,22). The cause for the 
increased mortality is estimated to be a consequence of the increased length of stay in the 
ICU, as well as the severity of the underlying illness affecting the patient. The increase in 
Length of hospital stay caused by a VAP has been estimated to be 2.03 days. (23) Along 
with the increase in hospital stay there is an associated increase in the cost to patients. In a 
developing country like India where costs for health care are borne by the individual 
patients the financial burden caused by a VAP has long term consequences for the future of 
the patient’s entire family.  
 
The causative organism for the VAP has been found to be an independent predictor of 
mortality, with high risk organisms such as Pseudomonas, Acinetobacter species and 
Xanthomonas maltophila being associated with a mortality rate of 65 %. (24) 
 
The increased mortality, the multidrug resistant causative organisms and the increased 
hospital stay and associated healthcare costs make the prevention, early identification and 
treatment of VAP a high priority among health care providers in the Intensive Care setting.  
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Prevention:  
 
Due to the greater understanding of pathophysiology of development of VAP, and its 
associated poorer prognosis, there has been an increased attention to preventive strategies.  
These strategies are aimed at, prevention of pooling of secretions, prevention of leakage from 
the ET tube by modifications of the tube and inhibition of biofilm formations.  
 
 Body positioning  
 
Current evidence based guidelines recommend that patients who are being mechanically 
ventilated should be placed in a semi- recumbent position, with head end elevation to 30-45 
degrees. The biological reasoning for this strategy is that, in critically ill patients the gastric 
pH is more alkaline than in healthy adults due to the enteral feeding, as well as stress ulcer 
prophylaxis.  This can lead to higher risk of gastric mucosal colonisation by enteric 
organisms. Gastroesophageal reflux of this acid can be aspirated which in turn leads to 
infections.  
 
The benefit of body positioning was demonstrated in a study where mechanically ventilated 
patients were randomised to semi-recumbent and supine positions and the position 
assessment was done once a day. It was found that there was a 75% reduction in the rate of 
VAP in the recumbent position group compared to the supine position group (8% vs 34% 
respectively, p=0.03)(25). Thus, semi-recumbent body position for the prevention of VAP 
has become the standard of care. 
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 Coated ET tube 
 
Figure 4: Scanning Electron Micrograph of an Endo-tracheal tube showing biofilm 
formation over the surface. B- RBC’s, macrophages, epithelial cells and cocci in pairs and 
chains embedded within the biofilm.  
 
The formation of biofilm is believed to play a role in shielding organisms from the effect of 
antibiotics, as well as providing an environment for bacterial growth and colonisation. Hence, 
using ET tubes coated with various antimicrobial agents have been tried. Of the agents used, 
chlorhexidine and sulfadiazine have been found to be of benefit in preventing biofilm 
formation and subsequent lung colonisation in animal models.  
 
However, problems faced with the use of biofilm inhibitors have been mucosal reactions to 
the chemicals used and as a result only silver sulfadiazine has been used in clinical trials. 
Another problem with coated ET tubes is that the effect of the coating is short lived. This is 
due to the ability of the gram negative organisms to form a biofilm over the coating. The 
Mucus Shaver is a device designed with a silicone rubber balloon with 2 or more rings which 
can effectively remove the secretions and bacterial biofilm and thus enable the ET tube 
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coating to maintain its efficiency. This device was tested in a randomised control trial 
involving 24 patients where the control arm received tracheal suctioning only while the 
treatment arm received tracheal suctioning with Mucus Shaver clearance of the ET tube sixth 
hourly until extubation. It was found that only 1 of 12 patients in the study group had 
colonisation as compared to 10 of 12 in the control group (p<0.01). There was no significant 
adverse effect associated with the use of the Mucus Shaver. (20)   
 
The use of biofilm-inhibitor coated ET tubes have not gained wide acceptance due to the 
limited number of human studies that have been done, and the questionable benefit observed 
in these studies. The cost involved in the use of this equipment has been another deterrent to 
its widespread usage.  A list of the different biofilm-inhibitors that have been tried is given 
below: 
 
 
 
Table 1: Endotracheal tube coating used to inhibit biofilm formation  
 
 
 
 
\ 
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 Subglottic Drainage of secretions 
 
 
 
 
Figure 5: Schematic representation of a continuous subglottic secretion drainage system  
 
 
The irritative effect of an ET tube and the obstruction caused by it hampers the normal 
functioning of the ciliary processes of the respiratory epithelium. This in turn leads to 
impaired clearance of respiratory secretions. These secretions can leak past the ET tube, due 
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to the imperfect seal produced by it and then track down into the lung causing infection. In 
order to break this cycle attempts have been made to improve the seal produced by the cuff of 
the ET tube, or to suction the secretions before they reach the lung parenchyma thereby 
preventing infection.  
 
Normal suctioning of the tube is inadequate as it is unable to clear the secretions and mucus 
that accumulates at the very tip of the ET tube. Hence ET tubes have been designed with 
specialised tips that allow for suctioning of the subglottic portion of the tube. This suctioning 
can either be intermittent or continuous. The debate about which of these is superior is an 
ongoing one.  
 
The use of suction for subglottic drainage of secretions was studied in a systematic review, 
and found that its use was associated with decreased duration of ICU stay, decreased duration 
of mechanical ventilation and an increase in time to first VAP. There were no associated 
adverse effects from the use of this device. (26) 
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CATHETER RELATED BLOOD STREAM INFECTIONS 
Epidemiology 
Central venous catheters (CVC) are being used with increasing frequency in hospitals both 
in an ICU setting as well as outside ICU’s. The infection of these CVC’s is becoming an 
increasingly large problem worldwide. The incidence of central line infections in the USA 
is estimated to be 1.65 per 1000 central line days amounting to 23,000 infection 
events.(27). This number is higher in the developing countries, with a large surveillance 
study conducted among ICU’s in Latin America, Asia, Africa and Europe reporting a 
pooled rate of 6.8 per 1000 central line days. (28). Studies done in India have also reported 
infection rates ranging from 8.75-9.6 per 1000 central line days. (29,30).  
 
One possible reason for the increased incidence in the developing countries is the lack of 
strict adherence to aseptic precautions during insertion of the lines, as well as the lack of 
clearly defined central line care bundles. 
 
Clinical features 
 
The importance of CRBSI is evident from the increased mortality that it causes, with one 
recent systematic review estimating almost two fold increased risk of mortality among 
those with CRBSI, even after matching for severity of illness. (31) Another study 
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estimated an increase in ICU stay by 13 days in those with CRBSI and a crude mortality 
rate of 28% (32). 
 
Risk factors 
 
The risk factors for CRBSI can be classified a patient, personnel and device related factors.  
 
The patient related factors include the degree of severity of the underlying illness, 
immunosuppression especially granulocytopenia, malnutrition, loss of integrity of skin 
especially in burns. (33)  
 
Operator related factors include degree of adherence to aseptic technique during placement 
of the line, as well as catheter site care.  
 
Catheter related factors are the site of placement of the line, the duration of the line and 
characteristics of the line such as the material, number of lumens etc. (34) 
 
Definitions 
 
The NHSN monitors the CRBSI, and publishes data on the yearly incidence of CRBSI. 
 The surveillance definition used by the NHSN is: 
“Isolation of a recognized pathogen from blood culture(s), the presence of clinical signs of 
sepsis and/or  shock (e.g., fever, chills, or hypotension), a determination that the infection is 
not from other sources, and confirmation that the organism is not a contaminant”(35).   
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Diagnostic criteria and methods  
 
Although the above definition serves as a useful guide, the clinical diagnosis of a catheter 
related infection still remains difficult because the clinical signs of inflammation at the 
catheter site are specific but not sensitive, and hence may not always be present. Secondly the 
clinical signs of systemic inflammation are very nonspecific and can be caused due to a host 
of other reasons, especially in a critically ill patient.  
 
For a patient with a suspected CRBSI, paired blood samples drawn from both the central line 
and a peripheral vein must be labelled and sent to the laboratory. One study demonstrated that 
if samples were not drawn from all the lumens of a multi-lumen catheter, then the infection 
could be missed in almost 30% of the patients. (36)  If a sample cannot be obtained from the 
central line, then two or more samples need to be taken from the catheter lumen and sent for 
culture. However, the need for cultures from all the lumens is not well defined in this 
setting.(37).  
 
Numerous methods for the diagnosis of CRBSI are available, with some necessitating 
catheter removal for facilitation of diagnosis, and other newer methods where the catheter can 
remain in place. These methods are listed in Table 1 
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Table 1: Methods for the diagnosis of a central line infection(38) 
  
42 
 
Paired quantitative blood cultures are considered to be the gold standard for diagnosis, but are 
time consuming and more expensive. On the other hand newer semi qualitative and 
radiometric methods have been developed that facilitate more rapid identification of growth 
in culture, and are less expensive. In addition the use of differential time to positivity (the 
detection of positivity in a blood culture drawn from a central line 2 more hours before the 
detection of positivity from a simultaneously drawn peripheral blood culture) has been 
demonstrated to be an accurate predictor of CRBSI. (39) 
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ACENITOBACTER BAUMANNII  
 
 
 
Figure 6: Gram stain appearance of Acinetobacter baumannii 
 
 
Microbiology 
 
This organism was first isolated in 1911 by Dutch microbiologist Beijerinck using a 
medium enriched with calcium acetate. He initially described it as Micrococcus calco-
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aceticus. The name ‘Acinetobacter’ was officially accepted in 1971 by the subcommittee 
on the Taxonomy of Moraxella and Allied Bacteria.(40) 
 
Currently, the genus Acinetobacter comprises ‘Gram-negative, strictly aerobic, non-
fermenting, non-fastidious, non-motile, catalase-positive, oxidase-negative bacteria with a 
DNA G+C content of 39% to 47%’. Of the 26 named species and nine genomic species in 
the genus, the medically significant ones have often been referred to as the A. calco-
aceticus complex. This comprises of four phenotypically similar organisms (Ac calco-
aceticus, A. baumannii, Acinetobacter genomic species 3 and Acinetobacter genomic 
species 13TU) which cannot be further differentiated from one another.(41) Of these, the 
most common and medically important pathogen is the Acinetobacter baumannii. 
 
The natural habitat of members of the Acinetobacter genus is thought to be ubiquitous as it 
is found in most samples of soil and water. As a pathogen it usually targets mucous 
membranes, and its ability to form biofilms over invasive devices makes the chronically ill 
ICU patient an easy target. (41). In addition the ability of Acinetobacter to remain viable 
despite weeks of exposure to dry hostile environments without desiccation, makes it a 
dangerous organism once introduced into a setting with critically ill patients where spread 
through fomites can have disastrous consequences.(42) 
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Mechanisms of drug resistance 
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Acinetobacter develops resistance to antibiotics by multiple mechanisms. They are known 
to develop resistance to quinolones by mutations in the genes gyrA and parC and can also 
develop aminoglycoside resistance by the same genes.  
 
AmpC b-lactamases are chromosomally encoded cephalosporinases seen in all members of 
the Acinetobacter genus. In normal circumstances, these enzymes have a low level of 
expression. But the insertion of a promoter sequence next to this gene causes 
overexpression thus leading to increased production of the cephalosporinase, leading to 
cephalosporin resistance.  
 
Acinetobacter has also been known to acquire b-lactamases, including serine and metallo-
b-lactamases, which leads to resistance to Carbapenems.  
 
Bacterial efflux pumps cause decreased antibiotic concentration in the periplasmic space, 
thus decreasing the dose of available effective antibiotic. To cause a clinically significant 
effect, these efflux pumps usually work in concert with b lactamases or other enzymes that 
inactivate, or modify the antibiotic action. Efflux pumps have been implicated in resistance 
to quinolones, tetracycline’s, chloramphenicol and tigecycline.(42)  
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Epidemiology and Clinical importance 
 
As has been elucidated earlier, the organism Acinetobacter has been known for a long time, 
but the recent interest in it is due to the increasing incidence of hospital acquired infections, 
especially those with Acinetobacter infections.  A 2008 report form the National Healthcare 
safety network estimated the frequency of gram negative bacteria associated health care 
associated infection. They found that Acinetobacter accounted for 8.4% of the Ventilator 
associated pneumonias and 2.2 % of all catheter related blood stream infections.(43) 
 
There also appears to be an increasing incidence of multi drug resistance among the isolates 
of Acinetobacter. One study performed in Turkey between 2003-2007 found increase in 
incidence of Imipenem resistant isolates form 43.3% at the beginning of the study to 72.9% at 
the end of the study period.(44)  Similar data was observed from an analysis of the Taiwanese 
nationwide surveillance database between 2003-2008 which found an increase in incidence of 
carbapenem resistant Acinetobacter baumannii from 4% to 62%(45).  
 
The increase in incidence of drug resistant Acinetobacter is important because, the 
acquisition of drug resistant isolates have been linked to increased mortality and increased 
length of hospital stay. (46) These in turn have economic implications in the form of 
increased cost of hospital care, in addition to increased cost due to the higher level of 
antibiotics required for clearance of the infection. An estimate of the economic burden of 
Acinetobacter infection in the intensive care setting found that the mean increase in length of 
stay was 25.23±10.59 days with an estimated cost per bed per day of $4397.50 (range $1000-
$8000) in the United States.  
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Hence there is an urgent need to combat this infectious agent with effective treatment and 
preventive strategies.  
 
 
 
 
Current treatment options and future implications 
 
In the case of antibiotic susceptible isolates of Acinetobacter baumannii, the treatment 
options are many and they include broad spectrum cephalosporins such as Ceftazidime. Beta 
lactamase inhibitor especially sulbactam has been shown to be highly effective against 
Acinetobacter and the combination of Ampicillin Sulbactam has been suggested to be at least 
as effective as Imipenem in susceptible isolates. (47) 
 
Carbapenems are another effective class of drugs that have a good bactericidal effect against 
Acinetobacter baumannii although the recent emergence of carbapenemase producing 
organisms has limited their clinical utility.   
 
Polymyxins, especially Colistin are being widely used as the agents of choice against 
Acinetobacter isolates that are resistant to the first line agents. Although there have been no 
randomised control trials to test the efficacy of this drug, a review of nine observational trials 
have estimated a cure rate of 66% with Colistin(48).  But the dosing difficulties and 
associated renal toxicities have been major hindrances to their widespread use.  
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Tigecycline has also been tried as a therapeutic option in multidrug resistant and extensively 
drug resistant Acinetobacter isolates. In one retrospective study among patients with 
multidrug resistant Acinetobacter baumannii infections, Tigecycline was associated with a 
good outcome among 81% of the patients.(49). This drug rapidly enters the tissues after 
administration and thereby has very low serum concentrations. Hence it is not advised to use 
this drug for patient with Acinetobacter bacteraemia, as it can lead to inadequate drug levels 
and impaired clearance of the organism thus facilitating development of drug resistance. 
 
Empirical antibiotic therapy is required in most clinical situations and the use of combination 
drugs for coverage of the broadest range of antibiotic susceptibility is a prudent option. 
Knowledge of the local antibiotic susceptibility profiles is essential for a rational choice of 
empirical therapy. For an area that is known to have multi drug resistant strains the use of 
combinations consisting of a Polymyxin or a Carbapenem would be a reasonable choice. 
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LACUNAE IN CURRENT KNOWLEDGE AND RATIONALE FOR THE STUDY 
 
Although infection with Acinetobacter has been linked to increased mortality, the causal 
association has not been definitively proved. Since these infections commonly affect patients 
in a critical care setting, the pre-morbid state of the host, the multiple comorbid illnesses, 
prolonged exposure to antibiotics and invasive devices are all factors that need to be 
considered in the event of mortality. Hence the debate of whether the Acinetobacter is just a 
coloniser in an already critically ill host versus Acinetobacter being the final definitive agent 
that caused the mortality has not been completely resolved. 
 
A systematic review of six matched case-control and cohort studies demonstrated a 
significant increase in mortality rate among those with Acinetobacter infection or 
colonisation, compared with others. (50) Another single center cohort study done by 
Robenshtok et al compared the mortality rates among 112 patients with Acinetobacter 
bacteraemia with 90 patients with Klebsiella bacteraemia. They found an increased mortality 
of 22.7% among the Acinetobacter group even after adjusting for possible confounders.(51) 
This study seems to demonstrate that Acinetobacter infections have a poor prognosis when 
compared to Klebsiella bacteraemia. However the possibility that they have not adjusted for a 
possible significant unknown confounder still remains. 
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The debate also extends to the question of whether the increased mortality observed among 
those with Acinetobacter infections can be attributed to the organism itself or the presence of 
drug resistance. Kwon and colleagues compared the mortality rates among patients with 
Imipenem resistant isolates of Acinetobacter with those who had Imipenem sensitive isolates 
of the same organism. They found an excess mortality of 25% among those with Imipenem 
resistant Acinetobacter bacteraemia.(52) On the other hand, a more recent study done in 
Thailand found no statistically significant difference in mortality rates between Imipenem 
resistant and Imipenem susceptible isolates on multivariate analysis after controlling for the 
confounding effects of severity of illness, inappropriate antibiotic therapy and primary source 
of bacteraemia. (53) 
 
It is not known whether the contradictory results of the studies can be attributed to just 
methodological differences, or whether they are due to differences in the characteristics of the 
patient populations and the standards of care available to them.  
 
There are no Indian studies which address the question of attributable mortality due to 
Acinetobacter infections.  
 
There is also a lack of data regarding the antibiotic susceptibility profile of Acinetobacter 
baumannii from the institution where this study was carried out.  
 
Hence this study was done to address the above inadequacies in knowledge.  
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MATERIALS AND METHODS  
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MATERIALS AND METHODS 
This study is a prospective cohort study among adult patients in Intensive Care Units (Medical 
ICU/ Medical HDU/Surgical ICU) who develop a hospital acquired infection (VAP or CR-BSI) 
as per the criteria defined below.   
Describe the setting 
Setting: 
This study was conducted at a tertiary care teaching hospital in South India. Most of the 
patients who are admitted in the critical care wards (MICU, MHDU, and SICU) arrive 
through the Accident and Emergency department. The Surgical ICU (SICU) also has post-
operative patients who are stabilised before shifting back to the wards. The population served 
by this hospital is very varied. There are a large number of patients who travel from all parts 
of India for medical care at this facility. In addition, this serves as a referral centre for many 
local hospitals as well. Hence the population of patients in this centre reflects a population 
distributed through the whole of India.  
Participants 
Adult patients admitted in the MICU, MHDU and SICU from January 1, 2013 to June 30, 
2014 
Inclusion criteria:  
 Above the age of 16 years  
             Exclusion Criteria:  
       Infections with Coagulase negative Staphylococci 
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Methodology: 
Case Ascertainment: 
  
Any patient who developed fever 48 hours after admission to the Intensive care unit was 
evaluated for VAP/BSI. Detailed physical examination was performed and appropriate 
blood investigations (total WBC count, differential WBC count, procalcitonin, arterial 
blood gas analysis), cultures (blood, urine, and endo-tracheal aspirate), Urine routine 
analysis and radiological investigations (chest X-Ray, ultrasound abdomen etc.) were 
undertaken to identify the source of the infection. The principal investigator also 
performed a clinical examination to determine any possible sources of infection. All the 
investigations were followed up carefully by the principal investigator to determine if the 
patient fulfilled the criteria for diagnosis of VAP or CRBSI. 
If patient fulfilled the criteria of VAP or BSI, then they were classified as study participants. 
After obtaining informed consent from the family members, the clinical details of the patient 
were entered into the clinical research form.  
 
The study participants whose clinical isolates grew Acinetobacter were classified as cases, 
while those whose clinical isolates grew other non-Acinetobacter organisms were classified 
as controls. 
 
If the culture grew more than one organism of which one was Acinetobacter, the patient was 
still classified as belonging to the Acinetobacter group (case).  Only those patients for whom 
none of the organisms on culture grew Acinetobacter species were classified into the Non-
Acinetobacter group.  
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The patient was followed every day until the final outcomes of death or discharge were 
attained. During the period of follow up the antibiotics used, the duration of antibiotic use, 
and the microbiological data on the organism and their antibiotic susceptibility profile was 
noted. 
 
If, during the course of hospital stay the patient developed another event of fever and fulfilled 
criteria for VAP or CRBSI, then the details were entered as a separate event, and followed up 
accordingly. Hence a single patient could have more than one HAI event during the course of 
a single hospital stay.  
 
If, during the course of the evaluation, it is found that the initial fever was caused due to a 
focus other than the lung or the CVC, then the patient was excluded from the study. 
The study methodology was evaluated and approved by the institutional review board (IRB 
min No: 8159 dated 9.9.2013).     
 
The overall algorithm for the study methodology is depicted below: 
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Patients 
->16 years 
MEDICAL 
ICU/HDU 
SURGICAL 
      ICU 
FEVER 
Clinically  
Suspected 
CRBSI 
Clinically 
Suspected 
VAP 
OTHER 
INFECTION 
EXCLUDED 
FEVER 
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CRBSI Case definition:  
 
A patient was suspected to have CRBSI based on the following criteria: 
• Patient has indwelling vascular catheter  
AND 
• Fever >100.4F OR hypothermia <97.7 F 
AND 
• Culture from both venous blood and vascular catheter with same organism  
OR 
• Culture from both venous blood and the catheter tip with the same organism  
AND 
• No other source evident for the bacteraemia. 
Other additional criteria for definition of CR-BSI: 
 
 If the blood culture had significant growth of organism, but the central line culture was not 
sent, or did not have any growth, but the clinical suspicion of CRBSI was high enough to 
warrant change of line site.  
 
If the central line culture had significant growth of organism (>15cfu) but the venous blood 
culture was negative (no growth), but the clinical suspicion of CR-BSI was high enough to 
warrant change of line site.    
The patients with BSI are further classified based on the blood and CVC cultures as 
Acinetobacter species infection or Non-Acinetobacter species infections. 
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The following flow chart is the algorithm for a suspected CRBSI. 
 
 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
Clinically suspected CRBSI 
Catheter culture and 
blood cultures 
EXCLUDED: 
Other source of 
infection found 
48-72 
HOURS 
CVC Related BSI: 
-Blood c/s and CVC c/s positive 
-Blood c/s positive+ CVC 
  
60 
 
                                                                                  
                                
 
 
VAP Case definition:  
 
If the patient was clinically suspected to have a VAP, then the Clinical Pulmonary Infection 
Score (CPIS) was calculated. A score more than 6 was highly suggestive of a VAP. 
Appropriate tracheal aspirate and blood cultures were taken as per the normal protocol in the 
ICU. The patient was reassessed again at 72 hours and a repeat CPIS score was calculated. 
The results of the ET aspirate were also followed up by this time.  Based on the two CPIS 
scores and the ET aspirate, the patient was classified as having ‘definite VAP’, ‘probable 
VAP’ and ‘no VAP’ only those who fulfilled criteria for ‘definite VAP’ were included as 
cases in the study.   
 
Based on the growth from the ET aspirate the patients were classified as Acinetobacter 
species and non Acinetobacter infections.  
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The following flowchart is an algorithm for a suspected VAP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinically suspected VAP 
Day1 CPIS      
score 
Ensure continuing routine 
care: 
-Blood cultures x2 
-urine analysis and cultures 
-Thoracocentesis for pleural 
fluid 
- Anti-atelectatic measures as 
needed. 
        Day 3 CPIS 
Definite VAP Probable VAP Not VAP 
-D1 CPIS >6+ ET 
Aspirate C/S positive 
-D1 CPIS <6 and D3 
CPIS >6 
-D1 CPIS score >6 
-ET aspirate- 
Negative 
-D1 CPIS <6+ 
D3 CPIS <6 
-ET Aspirate 
culture 
EXCLUDE: 
Non pulmonary 
source identified 
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Outcome Assessment: 
 
Primary Outcome: 
 
The primary outcome was to compare the mortality rate between cases (Acinetobacter 
infection) and Control (Non-Acinetobacter) among VAP and CRBSI. 
 
All patients enrolled in the study were followed up until the outcome of death or discharge 
was achieved.  
 
For the purpose of this study, the patients who were discharged against medical advice were 
analysed with the outcome of ‘death’.  
 
Secondary Outcome 
Microbiological outcomes: 
 
Since this was the first study which looked at infections caused by the Acinetobacter 
species, baseline microbiological data such as the incidence of Acinetobacter associated 
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VAP and CR-BSI was collected. This data was used to estimate the proportion of VAP 
and CR-BSI caused by Acinetobacter species.  
 
The antibiotic susceptibility profiles of the Acinetobacter isolates were also documented 
and analysed.   
 
 
Clinical Outcomes:  
 The Duration of ICU stay- measured in days from entry to ICU to either death or 
discharge to the wards and the duration of hospital stay- measured in days from entry 
to the hospital to death or discharge from the hospital was calculated and documented 
for both groups. This was later analysed to determine the duration of stay in each 
group.   
 
 Duration of ventilation- measured as ventilator free days. 
 Ventilator- free days (VFD) was defined as number of days between successful 
weaning from mechanical ventilation and day 28 after initiation of mechanical 
ventilation (VFD= 28- No of days on the ventilator). If the patient required 
mechanical ventilation beyond 28 days or if the patient died during the course of 
hospital stay the number of VFD was taken as 0. 
Successful weaning was defined as a continuous period of 48 hours or more off 
mechanical ventilation.    
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Sample Size Calculation:  
As per a recent study (unpublished) done in our institution, among patients admitted 
in MICU/MHDU by another investigator, the rates of VAP was found to be ~ 10%.  
(15 cases out of 146 patients included over 6 months). Based on this data we expected 
about 75 patients with VAP over our proposed study period of 17 months. 
 
Another study published from our ICU showed VAP to have a mortality rate of about 
52.7%. Assuming a 20% difference in mortality between the two groups, the sample 
size was calculated as shown below:  
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
 
Proportion in group I = .50 
Proportion in group II = .30 
Risk difference         = 0.2 
Power (%)                        = 80 
Alpha Error (%)                  = 5 
Side                            = 2 
Required sample size for each arm = 93 
 
Alpha Error (%)            Power (%)            Sample Size (n) 
                                         70                        73 
            5                          80                        93 
                                        90                        124 
----------------------------------------------------------------------------------------------------------------   
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Therefore 93 patients in each arm would yield a power of 80% at an alpha error of 5% 
to detect a 20% difference in mortality between the two groups. We calculated t-test, 
Chi-square test and ANOVA as appropriate for all analysis. Odds Ratio (OR) and 
confidence intervals (CI) were calculated and a ‘p’ value <0.05 was considered 
significant. Data was entered using Epi Data version 3.1 and analysed using SPSS 
version 22.  
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RESULTS  
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RESULTS 
Patient Characteristics: 
From January 2013 to June 2014 a total of 4047 patients were admitted in the intensive care 
units ( MICU/MHDU/SICU) out of which 134 patients fulfilled the case definitions for VAP 
or CRBSI as defined earlier. 2 patients were subsequently excluded from the study because 
although they fulfilled the criteria for a VAP, the colony counts of the sputum culture were 
low, and hence the microbiological diagnosis of VAP was questionable. 6 patients were 
excluded from the current analysis since they were still admitted in the hospital during the 
time of analysis and hence could not be included for the primary outcome measurement. 
Therefore a total of 126 patients were analysed as shown in the figure.  
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Number of patients admitted in Intensive care during 
study period (Jan 2013-June 2014) - 4047 
 MICU- 1236 
 MHDU- 1006 
 SICU- 1805 
Number of cases fulfilling 
case definition for 
VAP/CRBSI- 134 
8 cases excluded from analysis 
 6 cases still admitted in hospital at the 
time of analysis 
 2 cases excluded- inadequate colony 
counts on culture  
 
126 cases of VAP/CR-BSI analysed for 
outcomes  
77 Acinetobacter 
infections 
49 Non-
Acinetobacter 
infections 
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Comparison of baseline clinical characteristics: 
A total of 126 patients developed the HAI’s of interest during the study period, of which 77 
patients developed Acinetobacter infections and the other 49 patients had Non- Acinetobacter 
infections.  
 
The mean age of the patients in the Acinetobacter group was 46.5± 17.3 years while that of 
the Non-Acinetobacter group was 41.5± 17.4 years, with no statistically significant difference 
between the two groups. (p=0.11).  
 
44 (56.4%) were male in the Acinetobacter group while 34(43.6%) were female in the Non-
Acinetobacter group (p=1.9). 
 
The median APACHE III scores at baseline between the Acinetobacter and Non-
Acinetobacter groups of patients was 70 and 66 with inter quartile ranges of 47-96 and 39-83 
respectively. Although there is no significant difference between the groups, it can be seen 
that the cohort of patients who eventually developed Acinetobacter related HAI during the 
course of their hospital stay had higher APACHE III scores indicating that they were more 
critically ill, at presentation, than the other group. (****mention statistics) 
 
The median time to developing the HAI event was 7 days in both the groups, with no 
significant difference between them (p= 0.92). Similarly the median device day (the duration 
in days from insertion of the ET tube or vascular line to development of VAP or CRBSI 
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respectively), was also 7 days in both groups. This data suggests that the first week of 
hospital admission was the period of highest incidence of acquiring a HAI.  
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TABLE 2: 
PATIENT CHARECTERISTICS AT BASELINE: 
Characteristics  Acinetobacter 
group  
(N=77) 
Non- 
Acinetobacter 
group 
(N=49)  
95% CI Significance 
P- value  
Age (years)* 50, 29-62 41.46± 17.4 -1.1-11.4 0.11 
Male (%) 44 (56.4) 34(43.6)   1.90 
APACHEIII 
SCORE*   
70,(47-96) 66, (39-83) -2.2 – 19 0.12  
Time to developing 
HAI (days)* 
7, (5-9)    7, (4-13)   0.92  
Device day at the time 
of HAI ( days)* 
7, (4-9) 7, 5-9  0.49 
*Median, Inter Quartile Range.  
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Comparison of baseline comorbid conditions: 
 
The comorbid illnesses of the patients in the two groups were compared and have been 
shown in table 3. 
 
 11 patients (14.3%) of those with Acinetobacter related HAI had an underlying lung disease 
(defined as the presence of underlying asthma, COPD, interstitial lung disease or other 
chronic lung disease) compared to 3 (6.1%) of those in the Non Acinetobacter group. This 
difference, however, was not found to be significant.  
 
 Among the patients with underlying heart disease (defined as the presence of Ischemic Heart 
disease, Rheumatic Heart disease or Chronic Heart failure) 10 patients (12.9%) belonged to 
the Acinetobacter group compared to 6 patients (12.2%) in the non Acinetobacter group, 
which was not significantly different.   
 
22 (28.5%) and 10 (20.5 %) patients were diabetics in the Acinetobacter and Non 
Acinetobacter group, with no significant difference between them.  
 
10 patients (12.9%) and 7 patients (14.3%) in the Acinetobacter and Non- Acinetobacter 
group were chronic alcohol consumers. 16 patients (20.7%) and 5 patients (10.2%) of the 
patients were Hypertensive among the Acinetobacter and Non- Acinetobacter groups 
respectively. None of these were found to be significantly different between the two groups.   
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TABLE 3: COMORBID ILLNESSES AT PRESENTATION (PRIOR TO DEVELOPING 
THE HAI): 
 
Characteristics  Acinetobacter 
group  
(N-77) 
Non- 
Acinetobacter 
group 
(N-49)  
95% CI   Odds 
Ratio 
Significance 
P- value  
Diabetes 
 
22 (28.5%) 10 (20.4%) 0.62-4 1.56 0.41 
Hypertension   16 (20.7%) 5 (10.2%) 0.72-7.8 2.3 0.19 
Underlying lung 
disease* 
 
11 (14.3%) 3 (6.1%)   0.6-12.3 2.5 0.15 
Underlying Heart 
disease** 
10 (12.9%) 6 (12.2%) 0.3-3.6 1.07 0.88 
Chronic alcohol 
use  
10 (12.9%) 7 (14.3%) 0.29-2.86 0.953 0.9 
*Asthma or COPD or ILD or other chronic lung disease 
** Rheumatic Heart Disease or Ischemic heart disease or chronic heart failure 
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Comparison of baseline diagnosis: 
 
A comparison was done between the two groups, of the most common syndromes and 
presumptive diagnoses at the time of admission (refer table 4).  
 
33 patients (42.9%) and 8 patients (16.3%) in the Acinetobacter and Non-Acinetobacter 
groups respectively were admitted with infections (this included syndromic diagnosis such as 
sepsis or septic shock even if the source was not identified at the time of admission). 
 
There was a significantly higher proportion of ‘infection’ related syndromes in the 
Acinetobacter-related HAI group. The most common infections in this patient cohort were 
found to be scrub typhus and pneumonias (which could be community acquired pneumonias, 
or infective exacerbations of COPD).  
 
The other syndrome which was found to be significantly more common in the Non 
Acinetobacter group of patient was ‘poisoning/overdose’. Only 13 patients (16.9%) of those 
in the Acinetobacter group had come due to a poisoning or drug overdose compared to 17 
(34.7%) patients in the Non-Acinetobacter group. Most of the patients had presented with 
consumption of an Organophosphorous compound  
 
 The numbers of the patients with other diagnoses were not significantly different between 
the two groups. 
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TABLE 4: BASELINE DIAGNOSIS 
Syndromes  Acinetobacter 
group  
(N-77) 
Non- 
Acinetobacter 
group 
(N-49)  
95% 
C I   
 Significance 
P- value  
Infection 33 (42.9%) 8 (16.3%) 1.6-9.3  <0.001 
poisoning/overdose 13 (16.9%) 17 (34.7%) 0.16-
0.9 
 <0.05   
surgical/trauma 12 (15.6%) 10 (20.4%) 0.28-
1.8 
 0.48 
Neoplastic 4 (5.2%) 4 (8.2%) 0.14-
2.6 
 0.75 
Others 15 (19.5%) 10 (20.4%) 0.38-
2.30 
 0.95 
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Comparison of antibiotics given prior to developing HAI: 
 
The antibiotics given prior to the onset of the HAI were compared between the two groups 
(Refer Table 5). 
 
 21 patients (27.2%) with Acinetobacter related HAIs received macrolides while only 4 
patients (8.1%) with non- Acinetobacter related HAIs had received prior macrolides. 
Azithromycin was the most commonly used macrolide. The significant difference in usage of 
Azithromycin may be attributed to the previously noted difference in proportion of patients 
with infection related diseases admitted in the two groups.   
 
Regarding the use of Carbapenems among the Acinetobacter group, 35 patients (45.4%) had 
received prior Carbapenems in the hospital compared to 14 patients (28.5%) of those in the 
Non-Acinetobacter group. This difference was found to have a trend towards significance.  
 
 
There was no significant difference in the use of other classes of antibiotics between the two 
groups.      
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TABLE 5: COMPARISON OF ANTIBIOTICS GIVEN PRIOR TO HAI  
Antibiotic groups Acinetobacter 
group  
(N-77) 
Non- 
Acinetobacter 
group 
(N-49)  
95% 
confidence 
interval, 
Odds Ratio   
Significance 
P- value  
BL/BLI* 49 (63.6%) 26(53%) 0.33-5.52, 
1.5 
0.23 
Carbapenem 35(45.4%) 14(28.5%) 0.91-4.82, 
2.08 
0.08 
Macrolides 21(27.2%) 4(8.1%) 1.24-15.72, 
4.2 
<0.05 
Aminoglycosides 8(10.3%) 7(14.28%) 0.21-2.3, 0.7 0.707 
Tetracycline 5 (6.4%) 2 (4.08%) 0.26-12.73, 
1.63 
0.705 
Fluoroquinolone 5 (6.4%) 6 (12.2%) 0.12-1.99, 
0.5 
0.336 
BL** 5 (6.4%) 5 (10.2%)  0.14-2.61, 
0.61 
0.509 
Teicoplanin 5 (6.4%) 
  
4 (8.16%) 
  
0.17-3.70, 
0.78 
0.735 
Colistin 4 (5.19%) 6(12.24%) 0.09-1.69, 
0.39 
0.185 
*Beta lactam with Beta lactamase inhibitor 
** Beta lactam 
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Comparison of baseline laboratory results at the time of enrolment:  
 
The baseline Laboratory results at enrolment (at the time of acquiring the HAI) were 
compared between the two groups and are shown in Table 6.  
 
The median total leukocyte count was 12050 and 13400 cells/cu.mm among the 
Acinetobacter and non-Acinetobacter group respectively. The median lactate in mmol/L was 
1.7 and 1.3 among the two groups respectively. The median P/F ratios 241 and 234 mmHg 
respectively and the median Creatinine was 0.9mg/dl in both the groups.  
 
 None of the baseline laboratory values had any significant difference between the groups at 
the time of developing the Hospital Acquired infection.  
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TABLE 6: 
Characteristics  Acinetobacter 
group  
(N-77) 
Non- Acinetobacter 
group 
(N-49)  
p- value  
Total Leukocyte counts 
(cells/cu mm) Med, IQR 
12050, 
(9700-18400) 
13400, (9800-19500) 0.59  
Lactates (mmol/L) Med, 
IQR 
1.7, (1.2-2.5) 1.3, (1.1-2) 0.14  
P/F ratio ( mm Hg) Med, 
IQR 
241, (169.5-340) 234, (148.7-338.2) 0.29  
Creatinine (mg/dl) 0.9, (0.8-1.5) 0.9, (0.6-1.4) 0.21  
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Other additional descriptive characteristics: 
Distribution of Non-Acinetobacter related Hospital Acquired Infections 
Analysis of the clinical isolates of the 49 patients who had a non Acinetobacter related 
hospital acquired infection was done (refer Table 7) 
 
The most common Non-Acinetobacter organism in the clinical isolates was Klebsiella and 
Pseudomonas both of which were cultures in 23 of the isolates, forming 46.9% of the total 
number. The next most common organism was E-coli which was cultures in 11 isolates 
constituting 22.4%.  
Staphylococcus aureus was cultured in 10 isolates constituting 20.4%. As will be 
demonstrated in the following tables, the majority of Staph aureus isolates were obtained 
from central line related infections.  
Proteus and enterobacter species formed a minority.  
 The other organisms that grew on culture include sternotrophomonas and one isolate that 
grew Streptococcus pneumonia which was not community acquired.  
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TABLE 7: DISTRIBUTION OF NON-ACINETOBACTER ORGANISMS 
ORGANISM FREQUENCY (IN 
CULTURE) 
PERCENTAGE 
Klebsiella 23 46.90% 
Pseudomonas 23 46.90% 
E.coli 11 22.40% 
Staph aureus 10 20.40% 
Proteus 2 4.00% 
Enterobacter species 2 4.00% 
Others 5 10.20% 
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Distribution of organism by the type of Hospital Acquired Infection:  
Those patients who developed a CR-BSI, the commonest causative organism was Klebsiella 
which grew in 12 of the cultures constituting 24% of all the isolates with CR-BSI.  
Acinetobacter baumannii was isolated in 10 cultures, amounting to 20% of all the isolates.  
7 cultures (14%) grew E.coli while 5 cultures (10%) grew Pseudomonas and another 5 
cultures grew Staphylococcus aureus. 
   
TABLE 7: 
CR-BSI CAUSATIVE ORGANISMS: 
ORGANISM FREQUENCY (IN 
CULTURE) 
PERCENTAGE 
Klebsiella spp. 12 24% 
Acinetobacter baumannii 10 20% 
 
E.coli 7 14% 
Pseudomonas aeruginosa 5 10% 
 
Staph aureus 5 10% 
Enterobacter spp. 3 6% 
Proteus spp. 3 6% 
Others 5 10% 
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TABLE 8: 
VAP CAUSATIVE ORGANISMS: 
ORGANISM FREQUENCY (IN 
CULTURE) 
PERCENTAGE 
Acinetobacter baumannii 67 45.8% 
Pseudomonas aeruginosa 34 23.2% 
Klebsiella spp 20 13.6% 
Staph aureus 12 8.2% 
E.coli 9 6.1% 
Others 4 2.7% 
 
 
Among the patients who developed a VAP, Acinetobacter baumannii grew on 77 
endotracheal tube aspirates. This constituted 45.8% of all the VAP organisms. 
  
Pseudomonas was the second most common organism isolated constituting 23.2% of all 
isolates. 
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Klebsiella was found in 20 isolates constituting 13.6% while Staphylococcus aureus was 
isolated in 12 cultures constituting 8.2% of all the ET aspirate cultures. 
 
A comparison of the above two tables clearly shows the predilection that Acinetobacter 
species shows towards pulmonary infections. The distribution of organisms causing VAP is 
dominated by the Acinetobacter group which by itself constituted almost half of all the 
VAP’s observed in this cohort. This is in contrast to CR-BSI, where the commonest causative 
agent ( Klebsiella) only constituted 20% of the isolates. This observation just reinforces the 
already established microbiological fact that Acinetobacter favours respiratory epithelium 
both for colonisation and infection.    
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OUTCOMES: 
Primary Outcome: 
COMPARISON OF IN-HOSPITAL MORTALITY RATES   
TABLE 9: 
HAI group Death Discharge 
Acinetobacter infection 44 (57.1%) 20 (40.8%) 
Non Acinetobacter infection 33 (42.9%) 29 (59.2%) 
 
Total- 126 
Odds ratio for death from Acinetobacter- 1.933 (0.935-3.99, P-value- 0.074) 
 
INTERPRETATION: 
Although the mortality was approximately two-fold higher among patients with 
Acinetobacter HAI when compared to no-Acinetobacter HAI, this difference was not 
statistically significant.  
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Secondary Outcomes: 
 
Microbiological outcomes: 
 
PROPORTIONS OF BSI AND VAP DUE TO ACINETOBACTER  
TABLE 10 
 Acinetobacter Non Acinetobacter 
CR-BSI 10 (30.3%)  23 (69.7%) 
VAP 67 (72%) 26 (28%)  
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67 patients (72%) of VAP’s in this cohort were caused by Acinetobacter baumannii infection. 
On the other hand 23 patients (69.7%) of Cr-BSI were caused by a Non-Acinetobacter 
organism.  
 
This feature of the majority of VAP being caused by Acinetobacter can be attributed to the 
fact that these bacteria are known to thrive in moist environments such as the respiratory 
tract.  
 
The difference in VAP and CR-BSI occurrence among the Acinetobacter and Non-
Acinetobacter organisms was found to be statistically significant (P value<0.001). 
 
 This implies that if a patient in a critical care setting develops a VAP, then empiric therapy 
should be targeted towards Acinetobacter species, since these form almost 70% of all the 
VAP’s in this cohort.   
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 ANTIBIOTIC SUSCEPTIBILITY PROFILE OF ACINETOBACTER SPECIES: 
TABLE 11 
  Antibiotic classes Sensitive Resistant Total isolates 
tested 
AMINOGLYCOSIDES 31(14%) 190 (85.9%) 221 
BL/BLI* 5 (2.9%) 162 (97%) 167 
BETA LACTAMS  3 (1.4%) 208 (98.5%) 211 
CARBAPENEM 2 (1.3%) 143 (98.6%) 145 
CO-TRIMOXAZOLE 7 (10.2%) 61 (92.4%) 68 
AZITHROMYCIN 0 2 (100%) 2 
TETRACYCLINES 18 (24.6%) 55 (75.3%) 73 
LEVOFLOXACIN  3 (3.9%) 73 (96%) 76 
COLISTIN 74 (98.6%) 1(1.3%) 75 
 *Beta lactams-Beta lactamase inhibitors  
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Of all the Acinetobacter baumannii isolates, 85.9% were found to be resistant to 
aminoglycosides, 97% were resistant to BL/BLI and 98.5% were resistant to beta lactams. All 
isolates (100%) were resistant to Azithromycin and 96% were resistant to Levofloxacin. 
 
Antibiotic susceptibility testing to Carbapenems showed a 98.6% resistance rate to 
Carbapenems.  
 
98.6% of all the isolates were sensitive to Colistin, with only 1 isolate (1.3%) showing 
Colistin resistance.  
 
Based on the above data it can be concluded that in the event of a VAP in a critically ill 
patient in this institution, the causative organism is very likely to be Acinetobacter. The 
empiric antibiotic therapy should include Colistin, which can be downgraded based on the 
specific sensitivity profile of the patient’s isolate.  
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Clinical Outcomes:  
 
DURATION FREE OF MECHANICAL VENTILATION:  
TABLE 12 
days free from mechanical ventilation Acinetobacter 
N (%) 
Non- Acinetobacter 
N (%) 
 0 (>28 days on ventilator/ death) 45 (67.2%) 12 (46.2%) 
<10 days 11 (16.4%) 4 (15.4%) 
11-20 days  9 (13.4%) 9 (34.6%) 
>20 days 2 (3%)  1 (3.8%) 
 
Test of Significance:  
Analysis of Variance between groups (p-value) = 0.035 
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For those patients who developed a VAP, the duration of ventilator free days was calculated 
as per the protocol detailed earlier. 
 
The proportion of patients with ventilator free days of 0 was higher in the Acinetobacter 
group as compared to the other group. This indicates a larger proportion of poor ventilator 
outcomes (in the form of prolonged mechanical ventilation >28 days or death during course 
of treatment in hospital) among those with Acinetobacter related VAP.  
 
The group of patient with <10 days free of the ventilator in a month were also found to have a 
slightly higher proportion of Acinetobacter related HAI. Beyond 10 ventilator free days, this 
ratio was reversed.  
 
The differences in ventilator free days was found to be statistically significant (p-value 
<0.05). Therefore it can be concluded that Acinetobacter HAI causes a significant increase in 
the duration of mechanical ventilation and poorer ventilator outcomes (prolonged ventilation 
>28 days or death).  
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DURATION OF ICU STAY AND DURATION OF HOSPITAL STAY: 
TABLE 13 
 Acinetobacter  Non-Acinetobacter p-value  
Duration of ICU 
stay  
18, 13-28* 17,10-25 0.208  
Duration of Hospital 
stay (days) 
26, 16.2-46.5* 26, 15.5-37 0.76  
* Median, Inter-Quartile range  
 
The duration of ICU stay and Hospital stay was found to have no significant difference 
between the groups. 
 
The median duration of ICU stay among the two groups was 18 days and 17 days for the 
Acinetobacter and Non-Acinetobacter groups respectively with no significant difference in 
the duration of ICU stay between the two groups.  
 
 Similarly the median duration of hospital stay in both the groups was 26 days and with no 
statistically significant difference between the two groups.  
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The lack of a significant difference in the duration of hospital stay and ICU stay has to be 
understood in the light of the previous finding of poorer ventilator outcomes. The results 
show that Acinetobacter associated VAP are associated with poorer ventilator outcomes 
(prolonged ventilation or death) with no significant increase in duration of ICU stay.  
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DISCUSSION  
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DISCUSSION 
There is a global phenomenon of increasing rates of Acinetobacter species related hospital 
acquired infections. This is a ubiquitous organism with well-developed adaptive mechanisms 
to survive in a variety of environmental conditions. In the hospital environment 
Acinetobacter has been isolated from healthcare equipment, humidifiers, keyboards etc. and 
spread from person to person by hands of healthcare personnel. Their innate adaptability has 
led them to gain resistance to a wide variety of antimicrobial classes in a relatively short 
period of time. This has led to global alarm regarding the possible emergence of a pan 
resistant Acinetobacter ‘super-bug’.  
 
However, Acinetobacter species itself has none of the inherent virulence factors seen in a 
‘professional pathogen’ such as Staphylococcus aureus. In addition, the usual hosts for an 
Acinetobacter infection are critically ill patients whose immune systems are probably already 
underperforming due to their underlying illness. So the important question that needs to be 
addressed is “what is the true mortality attributable to Acinetobacter after considering all the 
host factors and underlying disease factors in a critically ill patient?” This study was 
performed in an attempt to answer this question.  
 
The cohort of patients included in this study consisted of critically ill adult admitted in the 
medical and Surgical ICU who developed a VAP or CR-BSI. The comparison of the baseline 
characteristics showed that the patients who eventually developed an Acinetobacter 
associated Hospital Acquired infection had a higher median APACHE III score at the time of 
admission. Although this difference was not statistically significant it is to be noted that this 
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organism tends to favour those who are more critically ill. This observation has been noted in 
other studies with Acinetobacter species.  
 
The centre at which this study was conducted in Southern India is an area which is endemic 
for Scrub typhus and has a large proportion of patients presenting with severe scrub typhus 
related ARDS and other major organ involvement (hepatitis, acute kidney injury, myocarditis 
etc.) especially during the rainy season. These patients often require prolonged intensive care 
with mechanical ventilator support until they recover organ functions, but overall have a good 
prognosis and chance for a full recovery. Pneumonias constituted the other major infection in 
the Acinetobacter cohort. The common factor in both these diseases is the presence of lung 
injury. In both Scrub typhus and severe pneumonia there is a degree of lung damage that 
occurs. In addition, there is a severe systemic inflammation with ongoing immune system 
activation. In this setting, it can be hypothesised that the underlying lung damage and the 
ongoing inflammatory response could make these critically ill patients more vulnerable for an 
Acinetobacter VAP. The current study was not powered to answer this question, but it needs 
to be addressed in future studies on Acinetobacter associated VAP’s. 
 
This centre in Tamil Nadu is surrounded by areas of agricultural land. Organophosphates are 
pesticides which are freely available and hence commonly used as agents for deliberate self-
harm. This is reflected in the large proportion of these patients in this study cohort. The 
patients with organophosphate poisoning commonly develop intermediate syndrome and 
require prolonged mechanical ventilation thus putting them at higher risk for the development 
of VAP. The significantly larger proportion of patients with poisoning/overdose in the Non-
Acinetobacter arm could also partially explain the lower median age group in that arm since 
these patients are usually younger individuals. 
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The difference observed among the groups was the significantly smaller proportion of 
patients with ‘poisoning’ in the Acinetobacter group when compared to the Non-
Acinetobacter group. Most of those who presented with poisoning had consumed an 
organophosphorous compound and required prolonged intubation and mechanical ventilation 
following the development of an intermediate syndrome. It has been hypothesised that 
Organophosphate compounds alter the cell mediated immunity such that there is a 
susceptibility to certain infections, especially Pseudomonas. In agreement with this 
observation, in our cohort of patients, those with organophosphorous poisoning 
predominantly developed infections with Pseudomonas and hence there was a significantly 
larger proportion of ‘Non-Acinetobacter infections’ seen.  
 
Comparison of antibiotics given prior to the onset of HAI showed that those patients who 
eventually developed an Acinetobacter related HAI had received Macrolides more commonly 
than those who did not. We think this is probably secondary to the predominance of scrub 
typhus and pneumonias in the Acinetobacter arm, rather than any effect of the antibiotic 
itself. A study done in Thailand compared Azithromycin with Doxycycline in severe scrub 
typhus. The study showed greater efficacy of Azithromycin than doxycycline in the treatment 
of severe scrub typhus.(54) Based on this evidence the institution where this study was 
conducted has been implementing a protocol of combination therapy with Azithromycin and 
Doxycycline in severe scrub typhus. For severe pneumonias, the IDSA/ATS guidelines 
recommends empiric therapy with Azithromycin and a beta lactam or beta lactam 
combination with beta lactamase inhibitor.(55). This is the treatment guideline that is 
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implemented at this institution. This can explain predominance of Azithromycin use in the 
Acinetobacter group.   
 
It is also important to note at this time the difference in Carbapenem use among the two 
groups. The Acinetobacter group had 35 patients (45%) who had already received 
Carbapenems prior to developing the HAI, as compared to 14 patients (28%) among those 
with Non-Acinetobacter related HAI. As per the Surviving Sepsis guidelines, in the event of 
severe sepsis of whatever cause, the empirical therapy of choice should include a carbapenem 
if a gram negative organism is suspected. The increased use of Carbapenems may once again 
reflect the severe of underlying illness among those who developed an Acinetobacter related 
HAI.  
 
Therefore at baseline itself the patients who developed Acinetobacter related HAI’s were 
more critically ill, with higher APACHE III scores at baseline, and were admitted more 
commonly with infectious diseases.   
 
Primary outcome assessment showed that our cohort of patients with Acinetobacter related 
HAI did not have a significant difference in mortality when compared to those with a Non-
Acinetobacter related HAI.  Although the odds ratio of death was 1.9, the 95% CI was very 
wide and included the null value of 1. This suggests a trend towards higher mortality among 
HAI caused by Acinetobacter spp. A larger study is needed to confirm this finding.  
 
Our hypothesis at the start of this study was that, since Acinetobacter is inherently a non- 
pathogenic organism, any mortality seen in these patients may be a factor of the critically ill 
state of the patients and not due to the infection.  
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In order to explore the possibility of underlying disease severity and host factors being a 
determinant of poor outcome among the HAI patients, we conducted univariate analysis of 
increasing APACHE III scores with mortality risk and compared them between 
Acinetobacter and Non-Acinetobacter species.  
 
This additional analysis is presented below.  
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 Death Discharge 
APACHE III<66 +AB HAI* 18 18 
APACHE III<66 + Non-AB HAI** 8 19 
APACHE III>66 +AB HAI* 25 15 
APACHE III>66 + Non AB HAI* 12 10 
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The comparison of baseline characteristics also did not show any statistically significant 
difference between the patients in the two groups. 
 
This suggests that Acinetobacter was not the causative agent for the outcome, but the 
outcome was most probably determined by other host factors. Hence the conclusion can be 
made the determinant for outcome of death or discharge among the two groups is probably 
independent of the organism causing the HAI. The acquisition of Acinetobacter does not 
increase the mortality risk. The Acinetobacter could just be an agent causing infection in an 
already critically ill host, and is not the determinant of mortality. 
 
 This finding is in agreement with other studies (39,53) which have found that the 
comparative mortality of Acinetobacter related HAI is not significantly different from that 
caused by other organisms. 
Jamulitrat et al conducted their study in Thailand and found that the mortality rate due to 
Acinetobacter bacteraemia was not significantly different from the mortality rate caused by 
infection with other organisms.(53)  
 
 However the results of our study results differ from that found by some other investigators  
(46,56). In the study done by Garcia et al, the mortality among Acinetobacter related HAI’s 
was found to be significantly higher even after matching with APACHE III scores. (56).  
 
One possible reason for this observed difference is the difference in patient characteristics. 
The studies that have found increase in mortality caused by Acinetobacter infections have 
been predominantly from developed countries (Spain, United States of America, Israel etc.) 
where the patient profile is different from that seen at our centre. Infections and poisonings/ 
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drug overdose formed the majority of the admission diagnosis in our cohort. This is likely to 
be very different from the other studies.  
 
Our study showed a significant increase in duration of mechanical ventilation but no increase 
in the duration of ICU and hospital stay.  
 
The antibiotic susceptibility profiles of the Acinetobacter isolates in our cohort showed 
significant proportion of resistance to Carbapenems with susceptibility to Colistin. This is the 
first study in this institution to look at the antibiotic susceptibility of these isolates and hence 
provides good baseline data for future comparative studies.  
 
The presence of such a high proportion of Carbapenem resistance is a matter of concern, 
especially since the only drug that seems to be sensitive is Colistin.  
Even among Colistin isolates there was 1 patient who developed a Colistin resistant 
Acinetobacter infection. Further follow up studies will be required to evaluate the 
significance of this finding.  
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LIMITATIONS   
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LIMITATIONS  
 
The calculated sample size was 93 in each arm, amounting to a total of 186 patients. Only 
127 patients have been analysed for the purpose of dissertation at this time. Hence 
conclusions that have been made based on this data have to be taken with the consideration 
that this study is underpowered at this time.  
 
A re-analysis done after achieving the required sample size may provide greater insight as to 
the true effect of Acinetobacter upon mortality. 
 
This cohort included patients from both Medical as well as Surgical ICU. The APACHE III 
scores for all the patients were calculated based on their parameters at the time of admission 
to the hospital (prior to the onset of the HAI). Although this appropriately reflected the 
disease severity in the medical cohort of patients, it underestimated the disease severity in the 
surgical patients, especially those who were taken up for elective procedures and developed 
complications requiring prolonged ICU stay.  
 
 
 
 
 
 
  
109 
 
 
 
 
 
 
 
 
 
 
 
 
  
110 
 
 
 
 
CONCLUSIONS AND 
RECOMMENDATIONS   
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CONCLUSIONS AND RECOMMENDATIONS   
1. The proportion of HAI (VAP and CR-BSI) caused by Acinetobacter spp. In this cohort was 61% 
2. Acinetobacter was the most common cause of VAP 
3. Prior receipt of Carbapenems was associated with Acinetobacter infections 
4. APACHE III scores were higher in patients who developed HAI due to Acinetobacter spp. 
5. Patients with ‘infectious syndromes’ were more likely develop Acinetobacter HAI when 
compared to other syndromes needing admission to ICU 
6. Almost all (98.6%) of the isolates of Acinetobacter were carbapenem resistant 
7. Colistin resistance among Acinetobacter  is rare 
8. Mortality was two-fold higher among Acinetobacter  HAI, though this difference did not achieve 
statistical significance 
9. Patients with  Acinetobacter HAI had poorer ventilator outcomes 
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In our cohort study of critically ill medical and surgical patients with VAP or CR-BSI, we 
found no significant increase in mortality rates among those with Acinetobacter related HAI’s 
compared to those with Non-Acinetobacter related HAI. However we found that the patients 
with Acinetobacter related HAI’s had significantly poorer ventilator outcomes (death or >28 
days on Ventilator) but no significant increase in ICU or Hospital stay compared to those 
with Non-Acinetobacter related HAI. We also found that in our centre a large proportion of 
VAP were associated with Acinetobacter, and most of them were resistant to Carbapenems 
but susceptible to Colistin.  
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Information Sheet 
This sheet is for your information regarding a research project that is being conducted in the ICU.  
During the period of stay of a patient within a hospital, it is possible to get new infections from the 
surroundings, nearby patients, or any equipment or devices that are used for the treatment of the 
patient. These infections are called Hospital acquired infections. Such infections can be harmful to 
that patient and can even be life threatening. Very little is known about these infections. This 
research study is being done in order to get a better understanding of Hospital Acquired infections 
especially in terms of what medicines ( antibiotics) can be used, as well as the overall outcome of 
patients who get these infections. 
One bacteria called Acinetobacter, has recently become a major cause for Hospital Acquired 
Infections. This study will be comparing the patients who have Hospital Acquired infections with 
Acinetobacter with those who have Hospital Acquired Infections due to other bacteria.   
For this study we will be carefully noting down the details of the patient such as the duration of 
fever, the results of tests ( like total counts, Creatinine, Procalcitonin etc) sent from the ICU as well 
as images ( like Chest X ray). We will also be noting down details about previous illnesses that the 
patient had ( such as Diabetes, Hypertension) which the patient had before being admitted in the 
ICU. We will also be noting down the causative organism for the Hospital Acquired Infection ( 
Acinetobacter, E. Coli etc) and  all the antibiotics being given to the patient as well as the duration of 
antibiotic use. We will be following up these details until the end of the patient’s stay in the hospital.  
All the information that we collect from the patients will be kept strictly confidential, and no 
personal details about the patient will be revealed to any third party. Only the persons involved in 
the analysis of the data from the study will have access to the medical and laboratory records of the 
patient 
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As explained above, this study only involves observation and recording of test results and 
medications given to the patient. No procedure will be done upon the patient apart from the routine 
care being provided to them from the ICU. There will be no risk of injury or harm to the patient due 
to their participation in this study.  
There will be no financial compensation for the patient or his/her family as well as no additional 
costs ( other than the costs of routine ICU care) to  the patient or family due to their participation in 
this study. 
The participation of the patient in this study is purely voluntary and he/she is free to withdraw from 
the study at any time. Refusal to participate in this study will not result in any change in 
treatment given to the patient, any penalty, or any loss of benefits to which the patient is 
otherwise entitled 
 For further questions kindly contact Dr Ajoy Oommen John , Department of Medicine 
CMC Vellore, Ph no: 7639195315. 
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Consent form 
Study Title: comparison of clinical outcomes of Hospital acquired infection (Ventilator Associated 
Pneumonia and Catheter related blood stream infections) among Acinetobacter spp with other 
bacterial pathogens among critically ill patients at a tertiary care centre in South India  
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 (iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
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Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Clinical Research Form  
Name:       Age:    Sex: Male / Female 
Address:  
 
Contact number:        
PRIMARY ADMISSION    /     RE-ADMISSION 
Date of hospital admission:      
Date of ICU admission:    Discharge date: 
Diagnosis at admission: 
Day of ICU admission at the time of recruitment:  
APACHE-III Score at the time of recruitment: 
 
Risk factors/Co-morbidities: (Circle features present at admission) 
Asthma COPD Other chronic lung disease 
Diabetes Ischemic heart disease Chronic heart failure 
Rheumatic heart disease Chronic renal failure Chronic liver disease 
Hypothyroidism on treatment Hyperthyroidism Anaemia 
Autonomic dysfunction HIV infection  Phaeochromocytoma  
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Illicit drug use Anti-cholinergic drug use Alcohol 
Others (list)  
 
ANTIBIOTICS RECEIVED PRIOR TO RECRUITMENT: 
1. 
2. 
3. 
4. 
5. 
 
 
Date of first fever:                                 CVC Day:___         ET Tube Day:_____ 
Infection type: BSI/ VAP  
Date         
Total WBC count         
Differential count         
Procalcitonin         
Blood lactate         
Urine routine 
analysis 
        
Creatinine         
eGFR         
 
Chest Xray    
 
CULTURES            1             2              3               4 
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BLOOD 
    
 
CATHETER 
    
 
 
ET ASPIRATE 
    
OTHERS           
 
    
ANTIBIOTICS AFTER HAI: 
1 . 
2. 
3. 
4. 
5. 
 
Outcome: Death/Discharge            
 Duration of Ventilator free days :                            
 Duration of ICU stay: 
Duration of hospital stay:  
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CPIS SCORE FOR VAP: 
 
CRITERIA FOR BSI:  
1) Patient has indwelling vascular catheter  
AND 
2) Fever (100.4F) OR hypothermia ,97.7C 
3) Culture from both venous blood and vascular catheter with same organism OR 
4) Culture from both venous blood and the catheter tip with the same organism 
AND 
No other source evident 
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